Subscribe
Thursday, September 24, 2026
20.6 C
Bengaluru
type here...
Subscribe
LeaderspeakThe Pharma Executive
2 min.Read

Excellence or Mediocrity—What Are You Building?

Anup Soans
By Anup Soans

Excellence is a choice. So is Mediocrity

Excellence is a choice. So is mediocrity.

Every day, in every interaction, in every decision you make, you are laying a brick. The question is not whether you are building something—you are. The only question is: What are you building? A cathedral or a shack? A legacy of excellence or a monument to mediocrity? I came across a quote recently that stopped me cold: “The path to excellence is arduous, but the alternative is mediocrity.”

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

MedicinMan Market Intelligence

A Tale of Two Cities: Peptides and Prescriptions

0
What our health choices reveal about education, access and...
MedicinMan Market Intelligence

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

0
MedicinMan Intelligent Insights When Air India CEO Tewolde Gebremariam...
MedicinMan Market Intelligence

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

0
Private equity does not pay a billion-dollar multiple simply...
MedicinMan Pharma Pulse

Medical Reps—Lessons From The West: The Old Model is Dead

0
The Core Conclusion The Western pharma industry is not simply...
Digital in Pharma

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

0
How wearables, diagnostics, AI and continuous monitoring are moving...

Topics

MedicinMan Market Intelligence

A Tale of Two Cities: Peptides and Prescriptions

0
What our health choices reveal about education, access and...
MedicinMan Market Intelligence

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

0
MedicinMan Intelligent Insights When Air India CEO Tewolde Gebremariam...
MedicinMan Market Intelligence

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

0
Private equity does not pay a billion-dollar multiple simply...
MedicinMan Pharma Pulse

Medical Reps—Lessons From The West: The Old Model is Dead

0
The Core Conclusion The Western pharma industry is not simply...
Digital in Pharma

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

0
How wearables, diagnostics, AI and continuous monitoring are moving...
Featured Article

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

0
RPG Active Pharma’s agreement to acquire the API and...
Healthcare Ececutive

Pharmacy of the World Pricing Paradox

0
India occupies an extraordinary position in global pharmaceuticals. It...
Featured Article

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

0
India has two very different pharmaceutical regulators living inside...
spot_img

Related Articles

spot_imgspot_img
Previous article
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
Next article
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?

MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More

Company

Headlines

A Tale of Two Cities: Peptides and Prescriptions

0
What our health choices reveal about education, access and...

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

0
MedicinMan Intelligent Insights When Air India CEO Tewolde Gebremariam...

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

0
Private equity does not pay a billion-dollar multiple simply...

Medical Reps—Lessons From The West: The Old Model is Dead

0
The Core Conclusion The Western pharma industry is not simply...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 | Crafted by SlamDunk